527 related articles for article (PubMed ID: 26075229)
21. Germline mutations in the DNA damage response genes BRCA1, BRCA2, BARD1 and TP53 in patients with therapy related myeloid neoplasms.
Schulz E; Valentin A; Ulz P; Beham-Schmid C; Lind K; Rupp V; Lackner H; Wölfler A; Zebisch A; Olipitz W; Geigl J; Berghold A; Speicher MR; Sill H
J Med Genet; 2012 Jul; 49(7):422-8. PubMed ID: 22652532
[TBL] [Abstract][Full Text] [Related]
22. [Genetic predisposition and ovarian cancer].
Coupier I; Gauthier-Villars M; This P; Stoppa-Lyonnet D
Rev Prat; 2004 Oct; 54(16):1757-62. PubMed ID: 15630879
[TBL] [Abstract][Full Text] [Related]
23. Targeted therapy for hereditary cancer syndromes: hereditary breast and ovarian cancer syndrome, Lynch syndrome, familial adenomatous polyposis, and Li-Fraumeni syndrome.
Agarwal R; Liebe S; Turski ML; Vidwans SJ; Janku F; Garrido-Laguna I; Munoz J; Schwab R; Rodon J; Kurzrock R; Subbiah V;
Discov Med; 2014 Dec; 18(101):331-9. PubMed ID: 25549704
[TBL] [Abstract][Full Text] [Related]
24. Lynch syndrome (hereditary nonpolyposis colorectal cancer) diagnostics.
Lagerstedt Robinson K; Liu T; Vandrovcova J; Halvarsson B; Clendenning M; Frebourg T; Papadopoulos N; Kinzler KW; Vogelstein B; Peltomäki P; Kolodner RD; Nilbert M; Lindblom A
J Natl Cancer Inst; 2007 Feb; 99(4):291-9. PubMed ID: 17312306
[TBL] [Abstract][Full Text] [Related]
25. The BRCA1/2 pathway prevents hematologic cancers in addition to breast and ovarian cancers.
Friedenson B
BMC Cancer; 2007 Aug; 7():152. PubMed ID: 17683622
[TBL] [Abstract][Full Text] [Related]
26. Breast cancer susceptibility testing: past, present and future.
Goldberg JI; Borgen PI
Expert Rev Anticancer Ther; 2006 Aug; 6(8):1205-14. PubMed ID: 16925486
[TBL] [Abstract][Full Text] [Related]
27. Homologous repair of DNA damage and tumorigenesis: the BRCA connection.
Jasin M
Oncogene; 2002 Dec; 21(58):8981-93. PubMed ID: 12483514
[TBL] [Abstract][Full Text] [Related]
28. Next-generation sequencing of the BRCA1 and BRCA2 genes for the genetic diagnostics of hereditary breast and/or ovarian cancer.
Trujillano D; Weiss ME; Schneider J; Köster J; Papachristos EB; Saviouk V; Zakharkina T; Nahavandi N; Kovacevic L; Rolfs A
J Mol Diagn; 2015 Mar; 17(2):162-70. PubMed ID: 25556971
[TBL] [Abstract][Full Text] [Related]
29. [HNPCC (hereditary non-polyposis colorectal cancer) or Lynch syndrome: a syndrome related to a failure of DNA repair system].
Manceau G; Karoui M; Charachon A; Delchier JC; Sobhani I
Bull Cancer; 2011 Mar; 98(3):323-36. PubMed ID: 21459714
[TBL] [Abstract][Full Text] [Related]
30. [Recommendations for the management of women with an increased genetic risk of gynaecological cancer].
Verheijen RH; Boonstra H; Menko FH; de Graaff J; Vasen HF; Kenter GG
Ned Tijdschr Geneeskd; 2002 Dec; 146(50):2414-8. PubMed ID: 12518519
[TBL] [Abstract][Full Text] [Related]
31. Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds.
Catts ZA; Baig MK; Milewski B; Keywan C; Guarino M; Petrelli N
Ann Surg Oncol; 2016 May; 23(5):1729-35. PubMed ID: 26727920
[TBL] [Abstract][Full Text] [Related]
32. Cancer predisposition genes: molecular mechanisms and clinical impact on personalized cancer care: examples of Lynch and HBOC syndromes.
Wang Q
Acta Pharmacol Sin; 2016 Feb; 37(2):143-9. PubMed ID: 26616728
[TBL] [Abstract][Full Text] [Related]
33. Beyond BRCA1 and BRCA2 wild-type breast and/or ovarian cancer families: germline mutations in TP53 and PTEN.
Blanco A; Graña B; Fachal L; Santamariña M; Cameselle-Teijeiro J; Ruíz-Ponte C; Carracedo A; Vega A
Clin Genet; 2010 Feb; 77(2):193-6. PubMed ID: 19930417
[No Abstract] [Full Text] [Related]
34. Genetic testing by cancer site: ovary.
Weissman SM; Weiss SM; Newlin AC
Cancer J; 2012; 18(4):320-7. PubMed ID: 22846732
[TBL] [Abstract][Full Text] [Related]
35. In brief: BRCA1 and BRCA2.
Foulkes WD; Shuen AY
J Pathol; 2013 Aug; 230(4):347-9. PubMed ID: 23620175
[TBL] [Abstract][Full Text] [Related]
36. Ovarian Cancer in Hereditary Cancer Susceptibility Syndromes.
Nakonechny QB; Gilks CB
Surg Pathol Clin; 2016 Jun; 9(2):189-99. PubMed ID: 27241103
[TBL] [Abstract][Full Text] [Related]
37. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.
Walsh T; Casadei S; Coats KH; Swisher E; Stray SM; Higgins J; Roach KC; Mandell J; Lee MK; Ciernikova S; Foretova L; Soucek P; King MC
JAMA; 2006 Mar; 295(12):1379-88. PubMed ID: 16551709
[TBL] [Abstract][Full Text] [Related]
38. Hereditary breast cancer: part I. Diagnosing hereditary breast cancer syndromes.
Lynch HT; Silva E; Snyder C; Lynch JF
Breast J; 2008; 14(1):3-13. PubMed ID: 18086272
[TBL] [Abstract][Full Text] [Related]
39. Hereditary predisposition to ovarian cancer, looking beyond BRCA1/BRCA2.
Minion LE; Dolinsky JS; Chase DM; Dunlop CL; Chao EC; Monk BJ
Gynecol Oncol; 2015 Apr; 137(1):86-92. PubMed ID: 25622547
[TBL] [Abstract][Full Text] [Related]
40. Lack of referral for genetic counseling and testing in BRCA1/2 and Lynch syndromes: a nationwide study based on 240,134 consultations and 134,652 genetic tests.
Pujol P; Lyonnet DS; Frebourg T; Blin J; Picot MC; Lasset C; Dugast C; Berthet P; de Paillerets BB; Sobol H; Grandjouan S; Soubrier F; Buecher B; Guimbaud R; Lidereau R; Jonveaux P; Houdayer C; Giraud S; Olschwang S; Nogue E; Galibert V; Bara C; Nowak F; Khayat D; Nogues C
Breast Cancer Res Treat; 2013 Aug; 141(1):135-44. PubMed ID: 23974829
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
